Cosgrove, Jason
Marçais, Antoine http://orcid.org/0000-0002-3591-6268
Hartmann, Felix J. http://orcid.org/0000-0002-4174-2276
Bergthaler, Andreas http://orcid.org/0000-0003-0597-1976
Zanoni, Ivan http://orcid.org/0000-0002-3423-7474
Corrado, Mauro http://orcid.org/0000-0002-0617-3274
Perié, Leïla
Cabezas-Wallscheid, Nina http://orcid.org/0000-0003-0870-0530
Bousso, Philippe http://orcid.org/0000-0002-6362-561X
Alexandrov, Theodore http://orcid.org/0000-0001-9464-6125
Kielian, Tammy http://orcid.org/0000-0001-7624-670X
Martínez-Martín, Nuria http://orcid.org/0000-0003-2309-8920
Opitz, Christiane A.
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Argüello, Rafael J.
Van den Bossche, Jan http://orcid.org/0000-0002-7852-2891
Article History
First Online: 11 April 2024
Competing interests
: R.J.A. is main inventor of SCENITH (Patent PCT/EP2020/060486) and is in the process of licensing the technology for commercialization of kits and providing patient-sample analysis services. In the past three years, C.A.L. has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures, and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1–ME1 pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015). T.A. holds several patents focused on imaging mass spectrometry and leads a startup on single-cell metabolomics incubated at the BioInnovation Institute. C.A.O. holds several patents on AHR activation and tryptophan catabolism and is founder and managing directors of cAHRmeleon Bioscience GmbH. The other authors declare no competing interests.